Journal
CURRENT OPINION IN PHARMACOLOGY
Volume 56, Issue -, Pages 52-60Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.coph.2020.10.021
Keywords
Biologics; Biomarkers; Inflammation; Monoclonal antibodies; Severe asthma
Categories
Ask authors/readers for more resources
Biological drugs have shown effectiveness in treating severe uncontrolled asthma, but there is a lack of head-to-head studies comparing the available molecules. Further molecular targets need to be identified to offer effective treatments for patients who do not respond to current biological drugs.
Biological drugs are approved to treat patients with severe uncontrolled asthma and are directed against mediators of type 2 immunity. These agents are effective in reducing the risk of exacerbation, maintaining asthma symptom control and reducing the need of systemic corticosteroids. Although biological drugs have revolutionized the management of the disease, to date there are no head-to-head studies across the current available molecules and there remains the need of specific biomarkers for the diagnosis, prognosis and response to treatment. Moreover, there is still an urgent need to identify further molecular targets to offer effective treatments for those patients who are not responsive to the currently available biological drugs, by moving upstream in the inflammatory cascade to inhibit multiple inflammatory pathways and/or identify effective nontype 2 immunity mechanisms.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available